BENIGN PROSTATIC HYPERPLASIA: Edited by Bob Djavan
With growing interest for screening, early detection and newer treatment options for prostate cancer, one may have the impression that benign prostatic hyperplasia (BPH) is a declining academic and clinical topic in our everyday practice.
However, if one studies the demographics of the population across the world, aging stands out to be one of the most prominent health issues and cost makers.
Symptoms related to BPH and bladder outlet obstruction (BOO) represent, therefore, a growing healthcare issue that needs further analysis, innovation and time adapted treatment and strategy.
This section in Current Opinion in Urology summarizes the current research, recommendations and investigations of some of the finest leaders, including a nobel price laureate among others.
From diagnosis to treatment, this issue covers indeed the newest trends. Bostanci et al. (pp. 5–10) review the correlation between inflammation and BPH and eventual consequences. Abdi et al. (pp. 11–16) summarize the current application of standard and new imaging techniques for patients with lower urinary tract symptoms due to BOO and BPH. Rick and Schally (pp. 17–24) reflect the view of an outstanding team of researchers around Dr Schally, a nobel price laureate, the ‘father’ of luteinizing hormone-releasing hormone therapy for prostate cancer. They report and investigate the role of hormonal manipulation in the pathophysiology but moreover in the treatment of BPH today. Lusuardi and Janetschek (pp. 25–29) review new emerging technologies for BPH. Marien and Shah (pp. 30–37) investigate BPH treatment options in the case of anticoagulation therapy, a growing source of concern in our everyday practice.
Finally, Espinosa (pp. 38–41) covers an extremely attractive topic, namely, ‘The role of nutrition in treating patients with symptoms related to BOO and BPH’.
Conflicts of interest
There are no conflicts of interest.